Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genscript Biotech Corp (OP:GNNSF)

2.420 UNCHANGED
Streaming Delayed Price Updated: 3:07 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genscript Biotech Corp

Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its... 
Via Benzinga
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal. 
Via Talk Markets
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
Via Talk Markets
3 DNA Stocks to Buy for the Synthetic Biology Revolution
Synthetic biology is a growing industry. The big winners will be DNA stocks that are able to sell to everyone, not just a small niche. 
Via InvestorPlace
The Next Big Disruptors? 3 Biotech Stocks Making Headlines.
Biotech stocks were hard-hit in 2022, but these disruptive names in the field of synthetic biology can be big winners in 2023. 
Via InvestorPlace
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in... 
Via Talk Markets
Three Pharma Stocks to Sell Before They Die
As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January. 
Via InvestorPlace
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
In a blockbuster agreement, Guangzhou’s Akeso out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion. Summit Therapeutics will pay $500 million upfront and... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.